Effect of ibuprofen and diethylcarbamazine on the hemodynamic and inflammatory response to endotoxin in the dog

European Surgical Research

Volumn 32, Issue 2, 2000, Pages 74-86

  Pinsky, Michael R ^c   Roman, A ^c   Buurman, W ^a   Content, J ^b   Vincent, J L ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

^c 604 Scaife Hall ^*

Author keywords

Cardiovascular function; Cyclooxygenase inhibition; Lipooxygenase inhibition; Septic shock; Tumor necrosis factor

Indexed keywords

DIETHYLCARBAMAZINE; ESCHERICHIA COLI ENDOTOXIN; IBUPROFEN; INTERLEUKIN 6; LACTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CELL COUNT; CONTROLLED STUDY; CYTOKINE RELEASE; DOG; ENDOTOXEMIA; ESCHERICHIA COLI; HEART OUTPUT; HEMODYNAMICS; INFLAMMATION; LACTATE BLOOD LEVEL; LEUKOCYTE; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034101835     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000008744     Document Type: Article

References (42)

1. Vincent JL, Domb M, Luypaert P, De Boelpaepe C, Van der Linden P, Bléeie S: Endotoxin shock model in the dog: A reevaluation. Prog Clin Biol Res 1987;236A:399.
2. Suffredini AF: Endotoxin administration to humans: A model of inflammatory responses relevant to sepsis; in Lamy M, Thijs LG (eds): Mediators of Sepsis (Update in Intensive Care and Emergency Medicine). Berlin, Springer, 1992, vol 16, pp 13-30.
3. Ertel W, Morrison MH, Wang P, Ba ZF, Ayala A, Chaudry IH: The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann Surg 1991;214:141-148.
4. Bernard GR, Reines HD, Halushka PV, Higgins SB, Metz CA, Swindell BB, Wright PE, Watts FL, Vrbanae JJ: Prostacyclin and thromboxane-A2 formation is increased in human sepsis syndrome - Effects of cyclooxygenase inhibition. Am Rev Respir Dis 1991;144: 1095-1101.
5. Foex BA, Quinn JV, Little RA, Shelly MP, Slotman GJ: Differences in eicosanoid and cytokine production between injury/hemorrhage and bacteremic shock in the pig. Shock 1997;8: 276-283.
6. Ogletree ML: Overview of physiological and pathophysiological effects of thromboxane A2. Fed Proc 1987;46:133-138.
7. Balk RA, Jacobs RF, Tryka AF, Walls RC, Bone RC: Low dose ibuprofen reverses the hemodynamic alterations of canine endotoxin shock. Crit Care Med 1988;16:1131
8. Matuschak GM, Pinsky MR, Klein EC, Van Thiel DH, Rinaldo JE: Effects of D-galactosamine-induced acute liver injury on mortality and pulmonary responses to Escherichia coli lipopolysaccharide. Modulation by arachidonic acid metabolites. Am Rev Respir Dis 1990;141:1296-1306.
9. Pinsky MR: Cardiovascular response in canine endotoxic shock: Effect of ibuprofen pretreatment. Circ Shock 1992;37:332.
10. Rogers FB, Dunn R, Barrett A: Diethylcarbamazine: A leukotriene inhibitor. Effects on red cell deformability in-vitro and in-vivo survival during endotoxemia. Int J Microcirc Clin Exp 1994;14:22-26.
11. Mansilla-Rosello A, Ferron-Orihuela JA, Ruiz-Cabello F, Garrote-Lara D, Fernandez-Mondejar E, Delgado-Carrasco ML: Differential effects of IL-1 beta and ibuprofen after endotoxic challenge in mice. J Surg Res 1997;67:199-204.
12. Leeper-Woodford SK, Carey D, Byrne K, Walsh C, Fisher B, Sugcrman HJ, Fowler AA: Histamine receptor antagonists, cyclooxygenase blockade, and tumor necrosis factor during acute septic insult. Shock 1998;9:89-94.
13. Michie HR, Spriggs DR, Manogue KR, Sherman ML, Revhaug A, O'Dwyer ST, Arthur K, Dinarello CA, Cerami A, Wolff SM, et al: Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 1988;104:280-286.
14. Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, Banks SM, MacVittie TJ, Parrillo JE: Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989;169:823-832.
15. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF: Antibodies to cachectin/ tumor necrosis factor reduce interleukin-1 beta and interleukin-6 appearance during lethal bacteremia. J Exp Med 1989;170:1627-1633.
16. Van der Poll T, Bueller HR, ten Cate H, Wortel CH, Bauer KA, Van Deventer SJ, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;3222:1622-1626.
17. Garcia MS, Galache JAC, Diaz JL, Cerda EC, Blasco JR, Aguinaga MAG, Reiz AN, Marin SR, Canaveral JJO, Sacristan del Castillo JA: Effectiveness and cost of selective decontamination of the digestive tract in critically intubated patients. Am J Respir Crit Care Med 1998;158:908-916.
18. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP: High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1991;91:23-29.
19. Preiser JC, Schmartz D, Van der Linden P, Content J, Vandenbussche P, Buurman W, Sebald W, Dupont E, Pinsky MR, Vincent JL: IL-6 administration has no acute hemodynamic effect in the dog. Cytokine 1991;3:1-4.
20. Pinsky MR, Vincent JL, Deviere J: Serum cytokine levels in human septic shock: Relation to multiple-systems organ failure and mortality. Chest 1993;103:565-575.
21. Rosenbloom AJ, Pinsky MR, Bryant JL, Shin A, Tran T, Whiteside T: Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction. JAMA 1995;274:58-65.
22. Ahmed T, Weichmen B, Wasserman MA, Muccitelli R, Tucker S, Marchette B: Prevention and reversal of endotoxin-induced pulmonary hypertension by a leukotriene antagonist. Eur Respir J 1988;1:145-152.
23. Hall-Angeras M, Saljo A, Hasselgren PO: Effect of methylprednisolone, indomethacin, and diethylcarbamazine on survival rate following trauma and sepsis in rats. Circ Shock 1986;20: 231-238.
24. Matuschak GM, Mattingly ME, Tredway TL, Lechner AJ: Liver-lung interactions during E. coli endotoxemia. TNF-alpha:leukotriene axis. Am J Respir Crit Care Med 1994;149:41-49.
25. Leeper-Woodford SK, Carey PD, Byrne K, Fisher BJ, Blocher C, Sugerman HJ, Fowler AAI: Ibuprofen attenuates plasma tumor necrosis factor activity during sepsis-induced acute lung injury. J Appl Physiol 1991;71:923.
26. Kettelhut IC, Fiers W, Goldberg AL: The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci USA 1987;84:4273-4277.
27. Knudsen PJ, Dinarello CA, Strom TB: Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin-1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol 1986;137:189-194.
28. 2, pH, temperature and hemoglobin saturation in the dog. J Appl Physiol 1966;215:195-201.
29. Landegren U: Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J Immunol Methods 1984;67:379-388.
30. Van Snick J, Cayphas S, Vink A, Uyttenhove C, Coulie PG, Rubira MR, Simpson RJ: Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci USA 1986;83:9679-9683.
31. Pinsky MR, Matuschak GM: Cardiovascular determinants of the hemodynamic response to acute endotoxeinia in the dog. J Crit Care 1986;1:18-31.
32. Vincent JL, Roman A, De Backer D, Kahn RJ: Oxygen uptake/supply dependency: Effects of short-term dobutamine infusion. Am Rev Respir Dis 1990;142:2-8.
33. Shoup M, He LK, Liu H, Shankar R, Gamelli R: Cyclooxygenase-2 inhibitor NS-398 improves survival and restores leukocyte counts in burn infection. J Trauma 1998;45:215-220.
34. Martich GD, Danner RL, Ceska M, Suffredini AF: Detection of interleukin 8 and tumor nevcrosis factor in normal humans after intravenous endotoxin: The effect of antiinflammatory agents. J Exp Mecd 1991;173:1021-1024.
35. Spinas GA, Bloesch D, Keller U, Zimmerli W, Cammisuli S: Pretreatment with ibuprofen augments circulating tumor necrosis factor-alpha, interleukin-6, and elastase during acute endotoxcmia. J Infect Dis 1991;163:89-95.
36. Bone RC: Phospholipids and their inhibitors: A critical evaluation of their role in the treatment of sepsis. Crit Care Med 1992;20:884-890.
37. Matthews WR, Murphy RC: Inhibition of leukotriene biosynthesis in mastocytoma cells by diethylcarbamazine. Biochem Pharmacol 1982;31:2129-2132.
38. Winslow C, Dorinsky PM: Regional blood flow distribution in endotoxin-treated dogs: Modification by ibuprofen. J Crit Care 1994;9:159-168.
39. Eichacker PQ, Waisman Y, Natanson C, Farese A, Hoffman WD, Banks SM, MacVittie TJ: Cardiopulmonary effects of granulocyte colony stimulating factor in a canine model of bacterial peritonitis. J Appl Physiol 1994;77:2366-2373.
40. Walvatne CS, Johnson AS, Wojcik LJ, Cerra FB: Cardiovascular response to acute and chronic endotoxemia in an awake, volume-resuscitated, canine model. Shock 1995;3:299-306.
41. Hoffman WD, Danner RL, Quezado ZM, Banks SM, Elin RJ, Hosseini JM, Natanson C: Role of endotoxemia in cardiovascular dysfunction and lethality: Virulent and nonvirulent Escherichia coli challenges in a canine model of septic shock. Infect Immun 1996;64: 406-412.
42. Cohen RI, Huberfeld S, Genovese J, Steinberg HN, Scharf SM: A comparison between the acute effects of nitric oxide synthase inhibition and fluid resuscitation on myocardial function and metabolism in endotoxemic dogs. J Crit Care 1996;11:27-36.